Background: Earlier this month, Ningi Research released a short report on Grail (GRAL), calling into question just about everything: Galleri’s clinical utility, its regulatory viability, and its commercial path.
False Positives and Real Questions: What the…
Background: Earlier this month, Ningi Research released a short report on Grail (GRAL), calling into question just about everything: Galleri’s clinical utility, its regulatory viability, and its commercial path.